Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity

Christian Kellner, Stefanie Derer, Katja Klausz, Sophia Rosskopf, Tim Wirt, Thies Rösner, Anna Otte, Elisa Cappuzzello, Matthias Peipp*

*Korrespondierende/r Autor/-in für diese Arbeit
2 Zitate (Scopus)

Abstract

Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certain Fc-mediated effector mechanisms triggered by monoclonal antibodies are essential for efficient antitumor activity. Today, next-generation monoclonal antibodies can be designed displaying tailor-made improved effector functions. The introduction of Fc-engineering technologies offers the potential to fine-tune Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, or complement-dependent cytotoxicity (CDC). Fc-engineered antibodies hopefully will overcome some limitations of current forms of antibody therapy.

OriginalspracheEnglisch
TitelAntibody Engineering
Redakteure/-innenDamien Nevoltris, Patrick Chames
Seitenumfang17
Band1827
ErscheinungsortNew York, NY
Herausgeber (Verlag)Humana Press Inc.
Erscheinungsdatum09.09.2018
Seiten381-397
ISBN (Print)978-1-4939-8647-7
ISBN (elektronisch)978-1-4939-8648-4
DOIs
PublikationsstatusVeröffentlicht - 09.09.2018

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Fc glyco- and fc protein-engineering: Design of antibody variants with improved ADCC and CDC Activity“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren